Do People With Diabetes Need to Fast Longer Before Surgery? Do People With Diabetes Need to Fast Longer Before Surgery?
New data find gastric contents after fasting aren ' t higher than nondiabetics, but an expert endocrinologist disputes that conclusion and GLP-1 agonists further complicate the picture.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 6, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Teucrium polium: new toxic effects added to the literature: a case report - Ghassa A, Ismail M, Alani LAA.
INTRODUCTION AND IMPORTANCE: Teucrium polium is one of the aromatic plants that grows in the Mediterranean region, and had been used as an herbal treatment for diabetes due to its hypoglycaemia effect. Although this plant is being studied now for its thera... (Source: SafetyLit)
Source: SafetyLit - May 6, 2024 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news
Intensive Therapy Beneficial in T2D and Early Hypertension Intensive Therapy Beneficial in T2D and Early Hypertension
Compared with standard antihypertensive therapy, intensive antihypertensive therapy may significantly benefit women with T2D whose hypertension is diagnosed earlier in life.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 6, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Clinical Summary Source Type: news
' Ozempic Ftw:' Elon Musk Touts Novo Nordisk's Blockbuster Drug As Solution To Childhood Obesity Problem
Tesla and SpaceX CEO Elon Musk has sparked a conversation about childhood obesity and potential solutions after giving his seal of approval for Novo Nordisk‘s NVO Ozempic, a GLP-1 agonist primarily prescribed to manage Type 2 diabetes. What Happened: On Sunday, Musk responded to a post on X about…#tesla #elonmusk #glp1 #calleymeans #billackman #donaldtrump #robertkennedyjr #apple #walmart #novonordisk (Source: Reuters: Health)
Source: Reuters: Health - May 6, 2024 Category: Consumer Health News Source Type: news
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
Eli Lilly (NYSE: LLY) stock has been a top performer thanks to runaway sales of its diabetes-turned-weight-management treatment. Despite nearly doubling over the past 12 months, Eli Lilly stock still has heaps of upside according to investment bank analysts who follow the century-old…#elililly #lly #barclay #lilly #tirzepatide #glp1 #gip #novonordisk #vikingtherapeutics #coryrenauer (Source: Reuters: Health)
Source: Reuters: Health - May 5, 2024 Category: Consumer Health News Source Type: news
Ozempic Maker Novo Nordisk Has Denmark ’s Economy Hooked
There is no escaping Ozempic and Wegovy. The diabetes and obesity drugs are a global phenomenon. They’ve won over the rich and famous, generated billions in sales and blown open a new market for weight loss drugs, which Goldman Sachs estimates will reach $100 billion a year by 2030. The…#ozempicandwegovy #goldmansachs #novonordisk #denmark #novo #danish #gatesfoundation #ukraine #subscribe #bloombergoriginals (Source: Reuters: Health)
Source: Reuters: Health - May 5, 2024 Category: Consumer Health News Source Type: news
Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making
The pharmaceutical industry is currently experiencing something of a renaissance thanks to the rise of blockbuster medications called glucagon-like peptide-1 (GLP-1) agonists. Perhaps the most well-known GLP-1 drugs are diabetes medication Ozempic and obesity care treatment Wegovy. Danish…#glp1 #danish #novonordisk #elililly #lly #fda #lilly #zepbound #jpmorgan #wegovy (Source: Reuters: Health)
Source: Reuters: Health - May 5, 2024 Category: Consumer Health News Source Type: news
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
The anti-obesity medication stock is way up, and there could be more fuel in the tank. Eli Lilly (LLY -2.77%) stock has been a top performer thanks to runaway sales of its diabetes-turned-weight-management treatment. Despite nearly doubling over the past 12 months, Eli Lilly stock still has heaps…#elililly #barclay #lilly #tirzepatide #glp1 #gip #novonordisk #vikingtherapeutics (Source: Reuters: Health)
Source: Reuters: Health - May 5, 2024 Category: Consumer Health News Source Type: news
Insulin Cost Is a Key Campaign Issue for Biden
President Biden says lowering the cost of insulin for seniors is among his proudest domestic policy achievements. He now faces the challenge of selling it to Americans of all ages. (Source: NYT)
Source: NYT - May 4, 2024 Category: American Health Authors: Zolan Kanno-Youngs Tags: United States Politics and Government Diabetes Insulin Health Insurance and Managed Care Prices (Fares, Fees and Rates) Drugs (Pharmaceuticals) Medicare Inflation Reduction Act of 2022 Presidential Election of 2024 Biden, Joseph R Jr Source Type: news
Oma 2024 oma 2024
Read clinically focused news coverage of key developments from OMA 2024Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 3, 2024 Category: Consumer Health News Tags: None Conference Coverage Source Type: news
New Perspective on Diabetic Neuropathy Emerges New Perspective on Diabetic Neuropathy Emerges
The idea that sensory neuropathy affects small fibers and that painful neuropathy affects large fibers must be reconsidered, said a diabetologist.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 3, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Diabetes Increases Risk for Functional Limitations in Older Adults
FRIDAY, May 3, 2024 -- Older adults with diabetes are more likely to develop functional limitations than adults without diabetes, according to a study published online April 16 in the Canadian Journal of Diabetes.Andie MacNeil, from the Institute... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 3, 2024 Category: Pharmaceuticals Source Type: news
iGlarLixi Safe and Effective in Inadequately Controlled T2D iGlarLixi Safe and Effective in Inadequately Controlled T2D
A once-daily injectable therapy of a fixed-ratio combination of insulin glargine and lixisenatide improved glycemic control, with low rates of hypoglycemia, in people with T2D in a real-world setting.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 3, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Clinical Summary Source Type: news
Launching an Obesity Medicine Practice? Key Considerations Launching an Obesity Medicine Practice? Key Considerations
As the treatment of obesity in the 21st century takes a monumental turn, the need for quality care is more pressing than ever: Tips for starting a new obesity-focused practice.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 3, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Small Bowel Microbiome Profiles Differ in Overweight/Obesity Small Bowel Microbiome Profiles Differ in Overweight/Obesity
Researchers have identified significant and specific variations in the microbial universe of the small intestine in overweight or obese adults compared with normal-weight peers.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 3, 2024 Category: Endocrinology Tags: Gastroenterology Clinical Summary Source Type: news
